Study details
Enrolling now
A Phase 1/2 Trial of SP-101 for Cystic Fibrosis (CF)
Spirovant Sciences, Inc.
NCT IDNCT06526923ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
15
Study length
about 2.3 years
Ages
18–65
Locations
4 sites in KS, MA, NY +1
About this study
This trial is testing a new treatment called SP-101 in adults with cystic fibrosis who cannot use CFTR modulators. The treatment will be given as part of a combination therapy with doxorubicin, and it will last 836 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take SP-101 and doxorubicin Cohort 1
- 2.Take SP-101 and doxorubicin Cohort 2
PhasePhase 1/Phase 2
Drugdoxorubicin Cohort 2
Primary goalIncidence and severity of adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
chemotherapy (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II)
Endpoints
Primary: Incidence and severity of adverse events
Body systems
Respiratory